These results therefore clearly demonstrated that the expression of ITGB2, VEGFA, CLDN4, OCLN, and SPP1 were significantly correlated with poorer clinical outcomes in serous ovarian cancer. The gene discussed is ITGB2; the disease is ovarian serous adenocarcinoma.